This Monday, May 15th, representatives from bioXclusters plus and Fenglin Group signed a Gateway Agreement to offer free services and guidance for SMEs in their operations in China. Services will include assistance in market access, private investment, clinical trials and soft landing packages. Continue reading
The European Strategic Cluster Partnership alliance on Personalised Healthcare, bioXclusters plus, which joins together four leading European Bioclusters –Biocat, BioM, BioPmed and Lyonbiopole –, has organized a trade mission that will be heading to Japan this October. This visit is organised in cooperation with the EU-Japan Centre. The “Biotech Cluster SME Mission” will take place from 9th to 14th October 2016. Continue reading
The bioXclusters partners are now back from their US Mission and would like to thank everyone who helped make their trip so successful and who, in addition, helped them gain a much greater understanding of the opportunities which this market represents and the life sciences environment in the US in general.
Internationalisation, especially in China, is considered sometimes to be something of an issue by SMEs and clusters. In life sciences, it is not an option. This sector’s activity cannot be restricted to national borders. Continue reading
The bioXclusters partners, along with some European SMEs, visited Shanghai in May 2013. Read the report about the mission which includes descriptions of the visits made and information about life sciences in this exciting and fast growing market.
From 10th to 12th September 2013, the European Commission travelled to Brazil with a selection of 9 European, life science clusters and four SMEs. The mission’s objective was to foster bilateral exchanges at different levels between European and Brazilian partners. To this end, the mission was organised around the BioPartnering Latin America event. Continue reading
Until recently, the history of the pharmaceutical industry in China was more about imitation than innovation.
According to a report by London-based market researcher Scrip Intelligence, approximately 40% of biotech sales in China come from biosimilars. This would explain why the market for biologics in China has been growing at a rate of more than 25% a year, while total sales of biotech drugs are still only $1.5 billion a year. Read more